{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T02:24:23Z","timestamp":1771467863839,"version":"3.50.1"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T00:00:00Z","timestamp":1709769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["T19K072180"],"award-info":[{"award-number":["T19K072180"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The Japanese national guidelines recommend significantly lower doses of carvedilol for heart failure with reduced ejection fraction (HFrEF) management than the US guidelines. Using real-world data, we determined whether initial and target doses of carvedilol in Japanese patients (JPNs) differ from those in US patients (USPs), especially in Asian Americans (ASA) and Caucasians (CA), and investigated differences in outcomes. We collected data from the electronic medical records, including demographics, carvedilol dosing, tolerability, cardiac functional indicators like EF, cardiovascular events including all-cause deaths, and laboratory values from the University of California, San Diego Health and Osaka University. JPNs had significantly lower doses (mg\/day) of carvedilol initiation (66 USPs composed of 38 CAs and 28 ASAs, 17.1\u00b116.2; 93 JPNs, 4.3\u00b14.2, <jats:italic>p<\/jats:italic>&lt;0.001) and one year after initiation (33.0\u00b121.8; 11.2\u00b16.5, <jats:italic>p<\/jats:italic>&lt;0.001), and a significantly lower relative rate (RR) of dose discontinuation and reduction than USPs (RR: 0.406, 95% confidence interval (CI): 0.181\u20130.911, <jats:italic>p<\/jats:italic>&lt;0.05). CAs showed the highest reduction rate (0.184), and ASAs had the highest discontinuation rate (0.107). A slight mean difference with narrow 95% CI ranges straddling zero was observed between the two regions in the change from the baseline of each cardiac functional indicator (LVEF, -0.68 [\u22125.49\u20134.12]; LVDd, \u22120.55 [\u22123.24\u20132.15]; LVDd index, \u22120.25 [\u22121.92\u20131.43]; LVDs, \u22120.03 [\u22123.84\u20133.90]; LVDs index, \u22120.04 [\u22122.38\u20132.30]; heart rate, 1.62 [\u22123.07\u20136.32]). The event-free survival showed no difference (<jats:italic>p<\/jats:italic> = 0.172) among the races. Conclusively, despite JPNs exhibiting markedly lower carvedilol doses, their dose effectiveness has the potential to be non-inferior to that in USPs. Dose de-escalation, not discontinuation, could be an option in some Asian and ASA HFrEF patients intolerable to high doses of carvedilol.<\/jats:p>","DOI":"10.1371\/journal.pone.0299510","type":"journal-article","created":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T18:58:51Z","timestamp":1709837931000},"page":"e0299510","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Lower doses of carvedilol in Japanese heart failure patients with reduced ejection fraction could show the potential to be non-inferior to higher doses in US patients: An international collaborative observational study"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4408-7019","authenticated-orcid":true,"given":"Makiko","family":"Maeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Humber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eisuke","family":"Hida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohito","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guannan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiori","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacinta N.","family":"Situ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinpei","family":"Nonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Sakata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Fujio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shirley M.","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2024,3,7]]},"reference":[{"key":"pone.0299510.ref001","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1007\/s11606-020-06070-z","article-title":"Changes in mortality in top 10 causes of death from 2011 to 2018","volume":"36","author":"JS Rana","year":"2021","journal-title":"J Gen Intern Med"},{"key":"pone.0299510.ref002","unstructured":"Japanese Ministry of Health, Labor and Welfare. Annual health, labour and welfare report 2021. 2021;02:63.Available from:https:\/\/www.mhlw.go.jp\/english\/wp\/wp-hw14\/dl\/02e.pdf"},{"key":"pone.0299510.ref003","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"145","author":"PA Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"pone.0299510.ref004","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1253\/circj.CJ-21-0431","article-title":"JCS\/JHFS 2021 guideline focused update on diagnosis and treatment of acute and chronic heart failure","volume":"85","author":"H Tsutsui","year":"2021","journal-title":"Circ J"},{"key":"pone.0299510.ref005","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S0140-6736(05)74356-7","article-title":"The cardiac insufficiency bisoprolol study II","volume":"353","author":"GA Drummond","year":"1999","journal-title":"Lancet"},{"key":"pone.0299510.ref006","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/01.CIR.90.4.1765","article-title":"A randomized trial of beta-blockade in heart failure. The cardiac insufficiency bisoprolol study (CIBIS). CIBIS investigators and committees","volume":"90","author":"CIA Committees","year":"1994","journal-title":"Circulation"},{"key":"pone.0299510.ref007","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR XL in chronic heart failure: Metoprolol CR XL randomised intervention trial in congestive heart failure (MERIT-HF)","volume":"353","author":"A Hjalmarson","year":"1999","journal-title":"Lancet"},{"key":"pone.0299510.ref008","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the carvedilol or metoprolol european trial (COMET): Randomised controlled trial","volume":"362","author":"PA Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"pone.0299510.ref009","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1161\/01.CIR.94.11.2807","article-title":"Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA investigators","volume":"94","author":"MR Bristow","year":"1996","journal-title":"Circulation"},{"key":"pone.0299510.ref010","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199605233342101","article-title":"The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol heart failure study group","volume":"334","author":"M Packer","year":"1996","journal-title":"N Engl J Med"},{"key":"pone.0299510.ref011","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"M Packer","year":"2002","journal-title":"Circulation"},{"key":"pone.0299510.ref012","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ahj.2003.07.023","article-title":"Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: The multicenter carvedilol heart failure dose assessment (MUCHA) trial","volume":"147","author":"M Hori","year":"2004","journal-title":"Am Heart J"},{"key":"pone.0299510.ref013","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ijcard.2012.11.051","article-title":"Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study","volume":"164","author":"H Okamoto","year":"2013","journal-title":"Int J Cardiol"},{"key":"pone.0299510.ref014","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1536\/ihj.16-157","article-title":"Investigators. High dose \u03b2-blocker therapy triggers additional reverse remodeling in patients with idiopathic non-ischemic cardiomyopathy: A lesson from a preliminary trial including the significance of left ventricular diameter and BNP change for reverse remodeling","volume":"57","author":"D Nitta","year":"2016","journal-title":"Int Heart J"},{"key":"pone.0299510.ref015","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/BF00544245","article-title":"Pharmacokinetics and bioavailability of carvedilol, a vasodilating beta-blocker","volume":"33","author":"E Vanmollendorff","year":"1987","journal-title":"Eur J Clin Pharmacol"},{"key":"pone.0299510.ref016","doi-asserted-by":"crossref","first-page":"e00496","DOI":"10.1002\/prp2.496","article-title":"Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology","volume":"7","author":"FN Agesen","year":"2019","journal-title":"Pharmacol Res Perspect"},{"key":"pone.0299510.ref017","unstructured":"Daiichi Sankyo Co. Ltd. Application form for the market approval submission of Carvedilol 2002:241\u20137. Avaulable from: https:\/\/www.pmda.go.jp\/drugs\/2002\/P200200033\/index.html, 27 June 2023."},{"key":"pone.0299510.ref018","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.clpt.2003.10.004","article-title":"CYP2D6 genotype and induction of intestinal drug transporters by rifampin predict presystemic clearance of carvedilol in healthy subjects","volume":"75","author":"T Giessmann","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"pone.0299510.ref019","doi-asserted-by":"crossref","first-page":"e011121","DOI":"10.1161\/JAHA.118.011121","article-title":"Beta-blockers and 1-year postdischarge mortality for heart failure and reduced ejection fraction and slow discharge heart rate","volume":"8","author":"JJ Park","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"pone.0299510.ref020","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2217\/pgs.11.20","article-title":"Carvedilol pharmacokinetics and pharmacodynamics in relation to CYP2D6 and ADRB pharmacogenetics","volume":"12","author":"D Sehrt","year":"2011","journal-title":"Pharmacogenomics"},{"key":"pone.0299510.ref021","unstructured":"National Library of Medicine. DbSNP short genetic variations: Release version: 20201027095038. Available from: https:\/\/www.ncbi.nlm.nih.gov\/snp\/rs1042714#frequency_tab., June 27, 2023."},{"key":"pone.0299510.ref022","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jacc.2011.03.057","article-title":"Influence of global region on outcomes in heart failure beta-blocker trials","volume":"58","author":"CM O\u2019Connor","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"pone.0299510.ref023","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jchf.2016.01.013","article-title":"Heart failure clinical trials in East and Southeast Asia: Understanding the importance and defining the next steps","volume":"4","author":"RJ Mentz","year":"2016","journal-title":"JACC Heart Fail"},{"key":"pone.0299510.ref024","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/cpt.1329","article-title":"Asian\" phenotype underestimates the genetic diversity of Asia yet overstates its impact on variability in drug disposition and pharmacodynamics","volume":"105","author":"R Singh","year":"2019","journal-title":"Clin Pharmacol Ther"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0299510","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,7]],"date-time":"2024-03-07T18:59:05Z","timestamp":1709837945000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0299510"}},"subtitle":[],"editor":[{"given":"Amirmohammad","family":"Khalaji","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2024,3,7]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3,7]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0299510","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,7]]}}}